gastroesophageal junction adenocarcinoma
1 curated biomarker
FDA-approved treatments
- ERBB2
- Perjeta (pertuzumab) [ema]
- Herceptin (trastuzumab) [fda]
- Enhertu (trastuzumab deruxtecan) [fda]
- Tukysa (tucatinib) [fda]
Prevalence
- ERBB2
HER2 is overexpressed or amplified in approximately 15%-20% of breast cancers and approximately 15%-20% of gastric/gastroesophageal junction adenocarcinomas.[fda]
Tests / detection method
- ERBB2
IHC, ISH/FISH, NGS (amplification calling)
Therapeutic pipeline
- ERBB2
- Bispecific HER2-targeted antibodies [fda]
- Next-generation HER2-directed antibody-drug conjugates (HER2-ultralow expression) [fda]
Recent news for gastroesophageal junction adenocarcinoma
PubMed Central · Aug 21, 2026
Clinicopathological Predictors of Pathological Response and Survival in Older Patients Undergoing Perioperative FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Read at PubMed CentralPubMed Central · Aug 20, 2026
Computational methods, clinical evidence, and translational readiness for artificial intelligence for HER2 assessment using silver in situ hybridization (SISH).
Read at PubMed CentralPubMed Central · Aug 19, 2026
The efficacy and safety of pembrolizumab in the treatment of HER2-negative advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis of emerging clinical data.
Read at PubMed CentralPubMed Central · Aug 19, 2026
Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma.
Read at PubMed Central